Axonis Therapeutics

About Axonis Therapeutics

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company dedicated to developing first- and best-in-class medicines targeting KCC2, a critical mediator of inhibition in the brain. The company aims to improve the lives of people suffering from neurological disorders by translating breakthrough discoveries from Boston Children's Hospital, Harvard, and Laval University.

Products & Services

AXN-027:A first-in-class oral KCC2 potentiator drug designed to restore functional inhibition for treating epilepsy, pain, and other central nervous system (CNS) pathologies. First-in-human trials began in 2024.

KCC2 Discovery Engine:A proprietary platform based on years of world-leading expertise, aimed at discovering and developing therapies targeting KCC2.

Specialties

Neuro-focused drug development KCC2-targeted therapies Neurological disorder treatments CNS pathologies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 115000000 MR: - FA: $115 million FAN: 115000000	D: 2024-10-30 FD: 2024-10-30	15 investors

Series A Latest

2024-10-30

$115.0M

15 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Yves De Koninck

Chair of Scientific Advisory Board

C

Corey Goodman

Executive Chairman & Co-Founder, Managing Partner at venBio Partners LLC

Z

Zhigang He

Scientific Advisor, KCC2 Neurobiology

C

Clifford Woolf, Ph.D.

Scientific Advisor, Pain

J

Jacqueline French

Scientific Advisor, Clinical Epilepsy

R

Roger Porter

Scientific Advisor, Epilepsy & Clinical Pharmacology

View 32 more team members with Pro

Unlock Full Team Directory

Recent News